WallStSmart

Astrana Health Inc (ASTH)vsThe Ensign Group Inc (ENSG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

The Ensign Group Inc generates 59% more annual revenue ($5.06B vs $3.18B). ASTH leads profitability with a 71.0% profit margin vs 6.8%. ENSG trades at a lower P/E of 35.0x. ENSG earns a higher WallStSmart Score of 57/100 (C).

ASTH

Hold

46

out of 100

Grade: D+

Growth: 7.3Profit: 6.0Value: 3.0Quality: 5.0

ENSG

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 6.0Value: 8.0Quality: 5.8
Piotroski: 5/9Altman Z: 2.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASTHSignificantly Overvalued (-508.0%)

Margin of Safety

-508.0%

Fair Value

$3.13

Current Price

$24.48

$21.35 premium

UndervaluedFair: $3.13Overvalued
ENSGFair Value (-0.3%)

Margin of Safety

-0.3%

Fair Value

$211.28

Current Price

$203.89

$7.39 premium

UndervaluedFair: $211.28Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ASTH3 strengths · Avg: 9.3/10
Profit MarginProfitability
71.0%10/10

Keeps 71 of every $100 in revenue as profit

Revenue GrowthGrowth
42.9%10/10

Revenue surging 42.9% year-over-year

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

ENSG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
20.2%8/10

Revenue surging 20.2% year-over-year

Areas to Watch

ASTH4 concerns · Avg: 2.8/10
Market CapQuality
$1.36B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
4.5%3/10

ROE of 4.5% — below average capital efficiency

Operating MarginProfitability
1.9%3/10

Operating margin of 1.9%

P/E RatioValuation
53.2x2/10

Premium valuation, high expectations priced in

ENSG3 concerns · Avg: 3.7/10
PEG RatioValuation
1.784/10

Expensive relative to growth rate

P/E RatioValuation
35.0x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
6.8%3/10

6.8% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : ASTH

The strongest argument for ASTH centers on Profit Margin, Revenue Growth, Price/Book. Profitability is solid with margins at 71.0% and operating margin at 1.9%. Revenue growth of 42.9% demonstrates continued momentum.

Bull Case : ENSG

The strongest argument for ENSG centers on Revenue Growth. Revenue growth of 20.2% demonstrates continued momentum.

Bear Case : ASTH

The primary concerns for ASTH are Market Cap, Return on Equity, Operating Margin. A P/E of 53.2x leaves little room for execution misses.

Bear Case : ENSG

The primary concerns for ENSG are PEG Ratio, P/E Ratio, Profit Margin.

Key Dynamics to Monitor

ASTH carries more volatility with a beta of 0.90 — expect wider price swings.

ASTH is growing revenue faster at 42.9% — sustainability is the question.

ENSG generates stronger free cash flow (133M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ENSG scores higher overall (57/100 vs 46/100) and 20.2% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Astrana Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company is headquartered in Alhambra, California.

The Ensign Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.

Want to dig deeper into these stocks?